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live into his or her ninth decade.1 These demographic
changes are reflected in the present-day cardiac surgery
practice, with an increased number of elderly individu-
als in need of highly sophisticated and complex cardiac
interventions, including transplantation. Heart trans-
plantation has indeed evolved into a highly successful
therapeutic modality for patients with end-stage car-
diomyopathy, with an actuarial survival of 80% at 1
year and 75% at 3 years for those patients who have
undergone transplantation after 1991.2 However,
despite many technologic advances and more refined
and specific immunosuppression developed during the
past decade, advanced age remains “the last frontier” in
heart transplantation and is still considered a con-
With the increased life expectancy of the Americanpopulation over the past few decades, elderly per-
sons are becoming the fastest growing segment of the
US population. The mean estimated life expectancy was
75.6 years in 1990 and is projected to increase further.
The average American who reaches 65 years of age will
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traindication in many centers. Data from the Registry
of the International Society for Heart and Lung
Transplantation (ISHLT) show that advanced age is still
a strong factor that adversely affects survival.2
Since the inception of our heart transplant program in
December 1988, carefully selected patients 70 years of
age and older have undergone transplantation for treat-
ment of end-stage heart disease not amenable to further
medical therapy or surgical intervention. This cohort of
patients represents 6% of our total heart transplant
patient population. Our initial experience with this group
of patients was reported in 1996.3 On the basis of satis-
factory results from this older population, as well as pos-
itive results in younger patients, we now report data on
15 patients 70 years of age and older who have under-
gone transplantation since 1994. In addition, these
patients are compared with 98 patients younger than 70
years of age who underwent transplantation during the
same time interval with a similar transplant protocol.
Patients and methods
Between November 1994 and May 1999, 113 patients
underwent orthotopic heart transplantation at Cedars-Sinai
Medical Center. This group included 15 (13%) patients 70
years of age and older who were retrospectively reviewed and
compared with the remaining 98 patients younger than 70
years of age. During the same period, 65 patients 70 years of
age and older were referred for transplantation, but only 44
patients were fully evaluated. Twenty-two patients were
refused for a variety of medical reasons (acceptance ratio =
0.50) and 4 patients died while awaiting a donor heart (18%
mortality in listed patients). The preoperative evaluations per-
formed in these older patient were more extensive than those
performed in younger patients, and they included a through
assessment of clinical conditions commonly seen in elderly
patients, such as colon, bladder, and prostate cancer, as well
as gastrointestinal studies to detect diverticular disease or
potential sources of blood loss. A vascular evaluation of
carotid and peripheral vascular disease was performed, and
hepatic, renal, and pulmonary function was thoroughly
assessed. An evaluation for osteoporosis was performed, and
Table I. Preoperative patient characteristics
Patient age group
Characteristic <70 y (n = 98) ≥70 y (n = 15) P value
Age at transplant (y)
Mean ± SD 55.8 ± 1 72.7 ± 2
Range 14-69.9 70-77 
Sex 1.0
Male 81 (83%) 13 (88%)
Female 17 (17%) 2 (12%)
Cardiomyopathy .49
Ischemic 52 (53%) 10 (67%)
Idiopathic 45 (46%) 5 (33%)
Sarcoid 1 (1%) — (0%)
NYHA class .42
II 7 (7%) — (0%)
III 33 (34%) 7 (47%)
IV 58 (59%) 8 (53%)
Diabetes mellitus 33 (34%) 2 (13%) .14
Body surface area (m2)
Male 2.0 ± 0.2 1.9 ± 0.1 .46
Female 1.6 ± 0.2 1.8 ± 1.5 .31
Hemodynamic factors
LVEF 21.8 ± 8.8 24.4 ± 5.0 .02
CO (L/min) 4.3 ± 1.3 3.7 ± 0.8 .15
CI (L · min–1 · m–2) 2.2 ± 0.7 2.0 ± 0.4 .04
TPG (mm Hg) 10.2 ± 5.6 7.7 ± 5.2 .09
PVR (Wood units) 2.7 ± 1.6 2.3 ± 1.5 .27
Creatinine (mg/dL) 1.3 ± 0.7 1.4 ± 0.5 .64
Range 0.4-6.4 0.9-2.4
Transplant status (UNOS)
1 63 (64%) 1 (7%)
2 35 (36%) 14 (93%)
CI, Cardiac index; CO, cardiac output; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PVR, pulmonary vascular resistance; TPG,
transpulmonary gradient; SD, standard deviation; UNOS, United Network for Organ Sharing.
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the impact of diabetes mellitus, if present, on end-organ func-
tion was carefully assessed. Finally, a psychosocial screening
was done by a psychiatrist and a social worker to verify com-
pliance and a clear understanding of the diverse implications
of transplantation. The presence of strong family support
with total and unrestricted commitment to transplantation
was mandatory. Patients were considered for transplantation
only if they had a positive outlook on life with a high degree
of personal and familial satisfaction. A work-related activity
was not essential, but because, by age definition, these
patients are at high-risk for transplantation, a less-than-opti-
mal evaluation indicated exclusion from consideration.
By comparison, during the same period, 469 patients younger
than 70 years of age were referred for transplantation, but only
247 of these were fully evaluated and 129 patients were listed
for transplantation (acceptance ratio = 0.52).
The preoperative characteristics of both patient age groups
are listed in Table I. The older age group had a higher preop-
erative left ventricular ejection fraction (P = .02) and cardiac
index (P = .04) than the younger group. The patients’ previ-
ous operations are listed in Table II. Donor heart characteris-
tics are given in Table III. Patients 70 years of age and older
had a higher incidence of female donors than the younger
group (P = .02). Of note, 4 older patients received allografts
from donors older than 50 years (range 52 to 56 years old)
and 7 younger patients received allografts from donors
between 50 and 55 years old. Waiting time before transplan-
tation is shown in Table IV. As shown in Table V, older
patients had a longer cardiac allograft ischemic time than
younger patients (P = .01). One older patient underwent com-
bined heart-kidney transplantation with allografts from the
same donor, and 5 patients in the younger group received
such combined transplants. The donor criteria used for the
older patients were similar to those used for younger patients,
although there was a stated willingness to use “borderline” or
“high-risk” donor organs for this group of patients. The organ
procurement agencies were alerted that we would evaluate
donor hearts that were deemed unsuitable for transplantation
by other transplant programs. This included older donors,
prolonged ischemic time, prolonged donor “down time,”
echocardiographic or angiographic abnormalities, high
inotropic support, and a high degree of donor/recipient
weight mismatch. Moderate to advanced undersizing of
donor hearts (eg, donor/recipient weight ratio of 0.8 to 0.5)
was undertaken when the recipient had a normal transpul-
monary gradient and pulmonary vascular resistance. The
exception to this high-risk donor organ criterion being allo-
cated to the elderly patients was applied to those patients who
were less than 70 years of age when listed for heart trans-
plantation but were septuagenarians at the time of transplan-
tation, thus receiving a “regular” allograft. In contrast, the use
of “high-risk” or “borderline” donors in the younger popula-
tion is currently very restrictive and highly selective, because
those patients can benefit from mechanical assist devices if a
donor organ is not available. However, in the early part of our
experience, those potentially compromised donor organs
were used in younger patients as well.
Endomyocardial biopsies were performed according to our
surveillance protocol or when acute rejection was clinically
suspected. Rejection episodes were treated if greater than 1B
(ISHLT classification).
Surgical technique. Two techniques for orthotopic heart
transplantation were used. In most patients (98%), our standard
technique was used. This consisted of total excision of the
recipient’s atria with cardiac allograft implantation performed
by means of bicaval and pulmonary vein anastomoses.4 In a few
patients (2%), a modified approach was used, namely, bicaval
and single left atrial anastomoses.5 The intraoperative decision
regarding the appropriate technique was based on the safety of
dissecting the posterior mediastinal adhesions surrounding the
posterior aspect of the left atrium.
Immunosuppressive therapy. Immunosuppressive thera-
py consisted of OKT3 induction therapy (5 mg intravenously
daily) maintained for 7 days, although some patients (those
with abnormal renal function with creatinine levels over 2.5
mg/dL or those patients undergoing combined heart-kidney
transplantation) received antithymocyte globulin (15 mg/kg)
for 7 days. Maintenance immunosuppressive therapy consist-
ed of cyclosporine (INN: ciclosporin) (5 mg/kg per day, for a
level of 200 to 400 ng/mL, as measured by monoclonal fluo-
rescence polarization immunoassay, within the first 12 weeks
after transplantation, and for a level of 120 to 200 ng/mL
thereafter, started postoperatively once the serum creatinine
level was <2.0 mg/dL); azathioprine (4 mg/kg preoperatively
and 2 mg/kg per day postoperatively, adjusted to the patient’s
white blood cell count) but switched to mycophenolate
mofetil (1000 mg twice daily) for all patients as of January
1997; and steroids (methylprednisolone sodium succinate, 1
g at removal of the aortic crossclamp intraoperatively, and
then 125 mg intravenously every 8 hours for 3 doses postop-
eratively, followed by prednisone, 0.25 mg/kg per day during
OKT3 therapy, increased to 0.5 mg/kg per day, and then
tapered in the subsequent 3 to 8 months).
Although the same immunosuppressive protocol was used
for older and younger patients, the levels of cyclosporine in
older patients were generally in the lower end of the intend-
Table II. Previous patient operations
Patient age group
Previous operations <70 y ≥70 y
CABG 33 4
AVR 2 0
MVR 2 1
CABG + MVR 1 2
CABG + AVR 0 2
AVR + MVR 2 1
Partial left ventriculectomy 2 0
LV aneurysmectomy 1 0
LVAD 1 0
Heart transplantation 3 0
Total 47 (48%) 10 (73%)
AICD 29 (30%) 4 (29%)
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting;
AICD, automatic implantable cardioverter defibrillator; MVR, mitral valve
replacement; LVAD, left ventricular assist device; LV, left ventricle.
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ed range. In addition, older patients were tapered off steroids
faster than younger patients, so most of them had stopped
receiving prednisone by the end of the sixth month after
transplantation.
Cytomegalovirus prophylaxis. Most patients were given 6
doses of intravenous immunoglobulin (500 mg/kg) within 1
week after transplantation, with 5 doses of intravenous
cytomegalovirus (CMV)–specific immune globulin (125
mg/kg) after the first intravenous immunoglobulin dose.
Intravenous ganciclovir was also administered (5 mg/kg
every 12 hours but adjusted for renal function) for 14 weeks
followed by oral ganciclovir (1000 mg twice daily but adjust-
ed for renal function) for an additional 38 weeks for those
patients who were donor CMV positive/recipient CMV nega-
tive (high risk). For those patients donor CMV positive/recip-
ient CMV positive and for those donor CMV negative/recip-
ient CMV positive (low risk), prophylaxis consisted of 6
doses of intravenous immunoglobulin and intravenous ganci-
clovir for 2 weeks followed by oral acyclovir (3200 mg daily
but adjusted for renal function) for 24 weeks. Prophylaxis for
high-risk patients spanned the first post-transplantation year,
whereas CMV prophylaxis for low-risk patients lasted the
first 6 months after transplantation.
Osteoporosis prophylaxis. Osteoporosis prophylaxis for
both groups of patients consisted of calcium carbonate
(Smith Kline Beecham Pharmaceutical, Philadelphia, Pa),
1.25 g per day; calcitriol (Roche Pharmaceuticals, Nutley,
NJ), 0.25 µg daily, and chelated magnesium (Freeda, New
Table III. Donor heart characteristics
Patient age group
Characteristic <70 y (n = 98) ≥70 y (n = 15) P value
Age (y) 28.3 ± 13 34.1 ± 17 .12
Range 11-55 10-56
Sex .02
Male 67 (68%) 5 (33%)
Female 31 (32%) 10 (67%)
Body surface area (m2)
Male 1.9 ± 0.3 1.7 ± 0.4 .55
Female 1.7 ± 0.2 1.7 ± 0.3 .75
Donor/recipient weight ratio 1.0 ± 0.2 0.9 ± 0.3 .22
Donor/recipient weight mismatch (<0.80) 27 (28%) 7 (47%) .14
Table IV. Waiting time before transplantation
Patient age group
Waiting time <70 y (n = 98) ≥70 y (n = 15) P value
UNOS status 1 (d) 27.7 ± 0.36 19*
UNOS status 2 (d) 140.6 ± 22.2 105.9 ± 23 .47
*The first (and only) patient underwent transplantation as UNOS status 1, but all subsequent patients (n =14) as UNOS status 2 according to our current protocol.
UNOS, United Network for Organ Sharing.
Table V. Intraoperative and postoperative characteristics
Patient age group
Characteristic <70 y (n = 98) ≥70 y (n = 15) P value
Allograft ischemic time (min) 170 ± 41 201 ± 49 .01
ICU stay (d) 9.4 ± 19.4 7.3 ± 4.2 .5
Range 2-166 4-18
Post-transplantation hospital stay (d) 16.3 ± 20.9 17.1 ± 14 .56
Range 2-188 9-61
Follow-up (mo) 59 60 .27
Mean ± SD 27.9 ± 17.1 33.3 ± 18.7
ICU, Intensive care unit; SD, standard deviation.
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York, NY), 1 to 2 g per day, adjusted according to the
patient’s renal function.
Statistical methods. Patients were stratified on the basis of
age (<70 years or ≥70 years of age). Data were presented as
frequency distributions and simple percentages. Values of
continuous variables were expressed as the mean ± standard
deviation. Patient preoperative group characteristics were
compared by either the 2-sample t test for continuous vari-
ables or the Fisher exact test for categoric variables. When
data were heavily skewed, data transformations were used to
normalize data. The t test was performed on the transformed
scale for these variables. A log-rank test (Mantel-Cox) was
used to compare the survival curves of the two age groups.
All testing was 2-sided using an alpha of .05. The statistical
software packages SAS (Statistical Analysis System 6.12,
SAS Institute, Inc, Cary, NC) and BMDP (Berkeley, Calif)
were used in all analyses.
Results
The 30-day or to-discharge operative mortality was
0% in the older group and 5.1% (5/98 patients) in the
younger group (P = 1.0). Actuarial survival at 1, 2, 3,
and 4 years was not statistically different between the
older and the younger patients (93.3% ± 6.4% vs
88.3% ± 3.3%, 84.9% ± 10.0% vs 77.9% ± 4.5%,
84.9% ± 10.0% vs 74.4% ± 5.0%, and 73.5% ± 13.6%
vs 69.1% ± 5.8%, respectively) (P = .64) (Fig 1). The
post-transplantation intensive care unit stay and total
hospital stay were similar in both groups, which trans-
lated into similar total hospital costs. Mean follow-up
time was the same in both groups (33.3 ± 18.7 months
in the older group and 27.9 ± 17.1 months in the
younger patients) (P = .27). The incidence of rejection
episodes was similar in both groups, with a mean num-
ber of rejection episodes of 0.13 ± 0.35 per patient in
the older group and 0.24 ± 0.5 per patient in the
younger group (P = .77) (Table VI). Similarly, the inci-
dence of CMV infection was similar in both groups,
with a mean number of CMV infection episodes of
0.14 ± 0.36 for the older group and 0.26 ± 0.5 for the
younger group (P = 1.0) (Table VII). The causes of
death in both patient populations are shown in Table
VIII. Nonspecific allograft dysfunction without allo-
graft coronary artery vasculopathy was the cause of
death in 2 elderly patients at 18 and 42 months after
transplantation, and another older patient died of pul-
monary embolus 6 months after transplantation.
Discussion
With the increasing number of elderly patients being
referred for cardiac interventions, cardiologists and
cardiac surgeons are faced with evaluating older
patients with end-stage heart disease not amenable to
further medical or conventional cardiovascular surgical
therapy for heart transplantation. Any intervention in
the older population should seek to improve functional
independence and quality of life at an acceptable risk.
However, despite meeting all criteria, older recipients
have been traditionally denied transplantation because
of the critical shortage of donor organs and because of
the assumption that selection for heart transplantation
should be based on patient potential for maximum ben-
efit in terms of functional recovery and length of sur-
vival. It has been argued that older patients have a post-
operative period characterized by higher infection rate,
higher incidence of malignant disease, greater func-
tional impairment, increased postoperative hospital
stay and associated costs, and poorer survival.6-10
However, the definition of advanced age for heart
transplantation among those reports is poorly defined,
having been reported as more than 55 years,10 60
years,8,9 and 65 years of age.6 These results are sup-
ported by data from the Registry of the ISHLT that
show a significant decrease in survival at 1 and 5 years
with increasing recipient age, especially in those over
65 years. Age remains a predictor of transplantation
mortality in a multivariate analysis even when adjusted
for other comorbidity factors. Further, the vast majori-
ty of risk factors known to affect the 1-year mortality,
advanced age included, persist at the 5-year point.2
However, the Registry data have to be taken only as a
reference point and in the right statistical context,
because there is significant variability regarding donor
and recipient selection and management among institu-
tions and because differences in the recipient risk fac-
tors may not be fully taken in considerations in the
variables collected for the multivariate analysis.
On the basis of these data, it is easy to understand the
natural reluctance of most heart transplant centers to
consider elderly patients as potential candidates.
Fig 1. Thirty-day operative survival and actuarial survival up
to 4 years for both patient age groups. ns, Not significant; SE,
standard error; HTx, heart transplantation.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 121, Number 3
Blanche et al 537
However, several studies have shown that heart trans-
plantation in older patients (defined as older than 55 to
65 years of age) can be performed successfully with
acceptable morbidity and mortality and excellent long-
term survival, comparable with those of younger
patients. These reports have concluded that the recipi-
ent’s age is not a significant risk factor for mortality,
and advanced age, although its definition is not uni-
form, should not be considered a major contraindica-
tion for heart transplantation.11-17 Notwithstanding the
fact that all of the reports are from single institutions
and involve a relatively small number of patients, most
transplant centers have advanced the upper age limit of
potential recipients within the past few years. In fact,
the mean age of heart transplant recipients has
increased steadily within the past decade, with the
number of patients 65 years of age undergoing trans-
plantation increasing from 1.4% (n = 24) in 1988 to
8.8% (n = 206) in 1998.18 Currently, the upper age limit
for heart transplantation remains undefined, although
according to available data, most transplant centers
consider 65 years of age a significant risk factor that
determines eligibility for transplantation.
In view of this compelling information, is there med-
ical justification to offer transplantation to older recip-
ients? Does an older patient deserve to be considered
for transplantation in light of the widely known short-
age of donor organs? How old is too old for heart trans-
plantation? Can elderly patients sustain the rigors of
transplantation, be rehabilitated, and have a productive
life? Do they deserve suboptimal or potentially com-
promised donor organs? Should they “jump ahead” of
younger patients on the transplant list if their condition
deteriorates? Is transplantation cost-effective? Most
important, do they do as well in the long term as
younger patients? The medico-ethical and moral impli-
cations in this regard are indeed complex but perhaps
can be partially addressed by the fact that liver and kid-
ney transplantation are selectively offered to patients
70 years of age and older. These issues have important
implications regarding the provision of expensive med-
ical care achieving cost-effective outcomes in the
fastest growing and largest segment of the population
with the current trend of managed care. 
Our present study, as well as our earlier studies,3,19
attempts to answer some of these questions, although it
could be argued that the profound selection bias for the
older patients may invalidate the statistical comparison
between the groups. However, the transplant acceptance
ratio for older and younger patients was similar (0.50 vs
0.52, respectively), indicating a highly selective criterion
in younger patients as well. Despite these potential lim-
Table VI. Incidence of rejection episodes (>1B)*
Patient age group
No. of rejection episodes < 70 y (n = 98) ≥ 70 y (n = 15) P value
0 76 (78%) 13 (87%)
1 21 (21%) 2 (13%)
2 0 0
3 1 (1%) 0
Mean ± SD 0.24 ± 0.5 0.13 ± 0.35 .77
SD, Standard deviation.
*According to the International Society of Heart and Lung Transplantation classification.
Table VII.  Incidence of CMV infection episodes 
Patient age group
No. of episodes < 70 y ≥ 70 y
of CMV infection (n = 98) (n = 15) P value
0 77 (79%) 13 (87%)
1 17 (17%) 2 (13%)
2 3 (3%) 0
3 1 (1%) 0
Mean ± SD 0.26 ± 0.5 0.14 ± 0.36 1.0
CMV, Cytomegalovirus; SD, standard deviation.
Table VIII. Cause of death
Patient age group
Cause of death < 70 y (n = 23) ≥ 70 y (n = 3)
Transplant atherosclerosis 7 0
Infection 6 0
Rejection 4 0
Mediastinal hemorrhage 2 0
Nonspecific graft failure 1 2
Cancer 1 0
Renal failure 1 0
Respiratory failure 1 0
Pulmonary embolus 0 1
itations, a reference point was needed to validate these
results. The results of the current study indicate that the
30-day or to-discharge operative mortality, actuarial sur-
vival up to 4 years, length of stay in the intensive care
unit and total post-transplantation hospital stay, inci-
dence of rejection, and incidence of CMV infection were
similar in patients less than 70 years of age and in those
70 years of age or older. Although we have not used
objective indicators to measure quality of life in either
group in this study, the subjective improvement and
indeed quality of life after transplantation for the older
patients was substantial and not clinically different from
that in younger patients. In addition, an aggressive
approach regarding the use of potentially compromised
or “suboptimal” allografts has been used in these elderly
patients with excellent clinical results, as previously doc-
umented.20,21 The relevant question is then whether we
should penalize older patients by placing them in a lower
priority status in the transplant list or by giving them a
suboptimal or potentially compromised donor heart on
the basis of their age. These are complex medical, ethi-
cal, and socioeconomic issues that go beyond the scope
of this study. 
Several lessons were learned from our initial experi-
ence, which remain valid over time. First, a highly
selective acceptance criterion for potential candidates
70 years of age and older was used to minimize post-
operative complications, which may adversely affect
survival and quality of life. 
Second, these elderly patients are listed for trans-
plantation only as United Network for Organ Sharing
(UNOS) status 2 to minimize perioperative morbidity.
Our current practice is not to upgrade these patients to
UNOS status 1 in the case of hemodynamic deteriora-
tion, even if intravenous inotropic support is needed to
temporarily stabilize hemodynamics. This practice pre-
vents elderly patients from “jumping ahead” of
younger patients waiting for transplantation. The use of
intra-aortic balloon pumps or mechanical assist devices
as a bridge to transplantation is probably not warranted
because older patients may not be able to tolerate relat-
ed complications. 
Third, it is clear to us that carefully selected patients
can withstand the rigors of transplantation and related
protocols, have a cost-effective outcome, achieve an
excellent functional result and quality of life, return to
an independent lifestyle, and continue to be productive
in society. 
Fourth, we have not observed an increased incidence
of rejection, CMV, or other infections in this group of
patients. In addition, although a purely observed phe-
nomenon without statistical validation, the incidence of
malignant tumors has been no greater in older patients
than in younger patients. This is perhaps due to the
proper tailoring of immunosuppressive protocols to
accommodate the decreased immune responsiveness
seen in elderly patients. The impact of an individual-
ized approach of the immunosuppressive protocol in
the final outcome of older transplant recipients cannot
be overemphasized. However, a continuous awareness
for the development of malignant disease with the nec-
essary surveillance for early detection is needed. 
Fifth, our experience with “borderline” or potentially
compromised cardiac allografts indicates that the selec-
tive use of marginally acceptable organs is compatible
with excellent cardiac function and survival.20,21 This
aggressive approach of liberalizing the criteria of
acceptability for donor hearts could alleviate the donor
shortage in cardiac transplantation by increasing the
number of available organs. However, extending the
age limit of potential candidates for heart transplanta-
tion into the seventies would certainly increase the
demand for organ donors and affect even further the
supply-demand donor heart mismatch. This increased
demand placed on an already fixed donor pool could
increase the waiting time and mortality in younger
patients needing a donor heart, which in turn may raise
additional moral questions and concerns. 
Sixth, as the indications for transplantation constant-
ly evolve and the results in selected septuagenarians
undergoing transplantation yield satisfactory results,
the reasons to justify the use of marginally acceptable
or “borderline” donor organs rather than “regular” allo-
grafts in elderly patients are becoming less clear. The
use of an “alternate list”22 seems also to discriminate
against these patients solely on the basis of their age.
The concept of matching high-risk donors with an
elderly patient population that may already be at high
risk may serve to expand the donor pool without com-
promising the lower risk and younger candidates.
However, this may artificially produce a lower survival
in the older patients, thus perpetuating the idea that
advanced age implies less than satisfactory results. 
Seventh, special attention should be given to the
common problems associated with elderly patients,
such as steroid-related osteoporosis, particularly during
the early months of transplantation. In addition, intense
rehabilitation and nutritional counseling should be pro-
vided to hasten functional recovery. In the late follow-
up period, close surveillance of renal and hepatic func-
tion, as well as a psychological profile, is needed to
detect behavioral changes such as depression that may
change the ultimate outlook for adequate functional
recovery. 
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Eighth, the presence of strong family support with
total and unrestricted commitment to the patient’s well-
being is essential, perhaps more so than in younger
patients. Although most of these elderly patients do not
carry an active full-time job, a high degree of personal
and familial satisfaction can be obtained with hobby-ori-
ented activities and easy noncompetitive sports, which in
turn may produce a more positive outlook in life. 
Finally, the issue of retransplantation for chronic
graft atherosclerosis in patients 70 years of age and
older who had undergone heart transplantation in earli-
er years, and are otherwise good candidates, remains
unclear. This subset of transplant recipients may even-
tually have to be addressed as more long-term sur-
vivors approach and cross the septuagenarian line.
In summary, our preliminary experience with heart
transplantation in selected patients 70 years of age and
older is encouraging and indicates that advanced age per
se (as defined in this report) is not a contraindication to
heart transplantation. However, care must be taken not to
interpret these data as an endorsement to pursue this
treatment modality in all septuagenarians who may be
candidates for heart transplantation. Instead, highly
selective criteria should be applied, identifying risks and
benefits individually. The medical and socioeconomic
implications are complex and the decisions involving the
use of available resources and technology in a cost-effec-
tive fashion can only be made with increased knowledge
regarding the unique issues associated with elderly
patients. Perhaps more moral and ethical questions have
been raised than answered with this study, but with the
aging of the American population and the proven effica-
cy of heart transplantation for end-stage heart disease,
these issues have to be addressed.
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also selected carefully, as the acceptance ratio for that group
of patients was 0.52 (129 patients listed for transplantation
out of 247 patients fully evaluated). 
Dr Robbins. In other words, you were being very selective
in these patients. 
Dr Blanche. That is correct.
Dr Robbins. I think that is one of the main reasons that
you get such good results.
Can you provide more specific details concerning the
selection criteria for the older patients with regard to periph-
eral vascular disease, diabetes, cancer history, and renal dys-
function? For instance, would you use any of those comor-
bidities as a contraindication for transplantation? Can you
give some general guidelines for these problems that often
arise in this group of patients? 
Dr Blanche. Diabetes is not considered a contraindication
unless the patient has severe end-organ damage. Severe
peripheral vascular disease is a contraindication, especially in
the presence of severe carotid artery disease. If renal dys-
function is mild, we do accept patients over the age of 70 for
transplantation. However, 1 patient in the older age group
underwent combined heart-kidney transplantation. With
regard to the other criteria, we screen the patients rigorously
for malignancy, particularly prostate and gastrointestinal,
more so than younger patients. 
Dr Robbins. The patients in the older cohort had a higher
mean ejection fraction than the younger patients. Since all the
older patients were in the status 2 outpatient category, it
would appear that the younger patients were sicker than the
older patients. Do you have any objective data such as
myocardial oxygen consumption that might help better define
the functional status of the older patients? 
Dr Blanche. Unfortunately, we do not have myocardial
oxygen consumption data on all patients for a meaningful sta-
tistical analysis. Obtaining this information has now become
routine as part of the preoperative evaluation, but during the
period of this study it was not always obtained.
Dr Robbins. Just in your general sense, is it true that the
older patients seem to be less debilitated and sick before the
operation?
Dr Blanche. Yes, perhaps so, because we know that we
will not place them in the transplant list as a status 1. These
patients wait an average of 105 days, so at least they have to
be fit enough to wait that long to receive a donor heart. 
Dr Robbins. There were 2 recipients in the older group
who died 18 and 42 months after transplantation from non-
specific allograft function. Did autopsy exclude graft coro-
nary artery disease as a cause of death?
Dr Blanche. Yes. Their autopsies showed they did not have
transplant atherosclerosis.
Dr Robbins. Finally, on the basis of the excellent results
achieved in the older group, would you use a marginal donor
from a younger patient in an older potential recipient if an
older potential recipient was not available on your list? How
would you prioritize the use of these donor hearts?
Dr Blanche. The use of a marginal donor in transplant
patients is well documented. With the availability of assist
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Discussion
Dr Robbins. This study is a retrospective analysis of the
outcome of cardiac transplantation in patients 70 years of age
and older compared with the results achieved in recipients
less than 70 years old. Fifteen older and 98 younger patients
received cardiac transplantation at Cedars-Sinai from 1994 to
1999. The authors concluded that cardiac transplantation can
be performed as successfully in patients over 70 years of age
as in younger patients and that advanced age should not be an
exclusion criterion for heart transplantation. They also stated
that perhaps more moral and ethical questions have been
raised than answered with this study, and I would agree with
that. Their program’s current policy is to list patients 70 years
and older on an alternative list so that they do not take donor
organs away from younger patients. Furthermore, these
patients receive borderline organs deemed unsuitable for use
by other transplant centers. This group of potential recipients
is only considered in the UNOS status 2 outpatient category.
As was pointed out, this presents a dilemma for the authors
as to whether older patients should be penalized by placing
them in a lower priority status in the transplant list and giving
them access only to suboptimal or potentially compromised
donor hearts on the basis of their age alone. 
I have a few observations and questions about these data.
Several studies including the most recent ISHLT Registry
report have identified recipient age over 65 as a predictor of
decreased survival at 1 and 5 years after cardiac transplan-
tation. Dr Bull and his colleagues from Utah presented a
paper at this meeting in 1995 about their results with car-
diac transplantation in patients over 60 years old. They
observed a 6-year actuarial survival of 54% for the older
patients and 72% for those younger than 60 years of age.
They pointed out that they did not use any unusual selection
criteria but treated the older patients the same as the
younger. The outstanding results achieved in this current
report are thought to be the result of proper patient selection
and tailoring of immunosuppressive protocols toward a
reduction in immunosuppression for the older recipients.
Sixty-five patients 70 years of age or older were referred for
evaluation. Forty-four were fully evaluated and 22 accepted,
for an acceptance rate of 33%. 
My first question is this: How many patients under the age
of 70 were referred and what was the acceptance rate for this
cohort of patients? 
Dr Blanche. The acceptance ratio for transplantation for
those patients older than 70 years of age was 0.50, thus indi-
cating high selective criteria. However, younger patients were
results can be achieved in patients 70 years or older after car-
diac transplantation. The statistical comparison between the
two groups of patients seems to be invalid because there was
such a profound selection bias for the older patients.
Adopting the general policy that age should not be a con-
traindication to cardiac transplantation should await longer-
term follow-up in a larger number of patients. The authors
ask the question in the manuscript, “How old is too old for
heart transplantation?” These data that were presented in this
paper do not provide an answer to this question, and the use
of highly selective criteria for listing older patients should
continue to be customized on an individual basis. 
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devices, perhaps I would place an assist device in a younger
patient and wait for a perfect heart. We have no problems
using a marginal donor for an older patient because many
studies show that marginal donors in the long run perform as
well as “regular” donors. We are in the process of revising our
protocols. In view of the good results obtained in the older
patients, perhaps older recipients should receive the same
type of allografts as younger patients. In other words, they
should not be discriminated against because of their age. 
Dr Robbins. Right. Another possibility is that the younger
patients might receive those marginal hearts.
In summary, this group has demonstrated that satisfactory
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